Latest Research And Development News

AFT Pharmaceuticals has reported a robust first half of FY26, posting a 33% revenue increase to a record $114.9 million and returning to profitability amid strong growth in Australia and international markets. The company’s advancing R&D pipeline and strategic licensing deals position it well for ambitious FY27 targets.

Nufarm Limited posted a $165.3 million statutory loss for FY25, driven by significant restructuring charges and omega-3 price declines, while announcing a CEO transition effective January 2026.

Clover Corporation Limited reported a standout FY25 with robust revenue growth and a sharp rise in profitability, underpinned by strategic market expansion and product innovation. The company’s strengthened balance sheet and optimistic FY26 outlook signal continued momentum.

TechnologyOne has reported a robust FY25 with profit before tax up 19% and ARR reaching $554.6 million, propelled by its SaaS+ platform and UK market expansion. The company sets an ambitious $1 billion ARR target by FY30, underpinned by strong R&D investment and AI integration.

TechnologyOne has delivered a standout FY25 performance, beating profit guidance and accelerating its ARR growth well ahead of schedule, powered by its innovative SaaS+ model and strong UK market traction.

Critical Resources Limited has secured a 12-month exclusive option to evaluate advanced solid-state lithium-ion battery technology from the South Dakota School of Mines & Technology, aiming to enhance battery safety, performance, and commercial potential.

Catapult Sports Ltd has reported a robust first half of FY26, with a 19% increase in Annualized Contract Value and a 50% jump in operating profit, driven by strategic acquisitions and strong SaaS growth.

Aurora Labs has entered a strategic MOU with Ares Armaments to co-develop advanced metal components for defence, aiming to revolutionise small-arms manufacturing with additive technology.

Algorae Pharmaceuticals has announced a non-renounceable Loyalty Options Offer to eligible shareholders, aiming to raise up to $337,678 before costs, with potential additional capital of $4.7 million if all options are exercised. The capital raise supports the company’s pharmaceutical and AI research and development ambitions.

Genetic Signatures Limited unveiled a year of strategic transformation and robust financial growth at its 2025 AGM, highlighting leadership renewal and a sharpened commercial focus. The company’s FY25 revenue jumped 66%, driven by strong product demand and expanded market presence.

New Zealand Coastal Seafoods (ASX – NZS) marked a key milestone with its MV Bluefin's maiden Coral Sea fishing trip and is advancing plans for a $2 million capital raise amid strategic rebranding.

Anteris Technologies has gained FDA approval to start patient recruitment in the US for its pivotal PARADIGM Trial, following initial European regulatory success. The company advances manufacturing and clinical readiness as it pushes toward key regulatory milestones.